FY2025 Earnings Forecast for INSP Issued By Leerink Partnrs

Inspire Medical Systems, Inc. (NYSE:INSP) – Stock analysts at Leerink Partnrs boosted their FY2025 EPS estimates for shares of Inspire Medical Systems in a research report issued to clients and investors on Monday, November 3rd. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings of $1.60 per share for the year, up from their previous forecast of $1.06. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ FY2026 earnings at $1.65 EPS, FY2027 earnings at $2.55 EPS and FY2029 earnings at $4.36 EPS.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.53. The company had revenue of $224.50 million during the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 EPS.

A number of other brokerages have also issued reports on INSP. UBS Group set a $89.00 price target on shares of Inspire Medical Systems and gave the company a “neutral” rating in a research note on Monday, September 22nd. JPMorgan Chase & Co. lowered their price target on shares of Inspire Medical Systems from $110.00 to $82.00 and set a “neutral” rating on the stock in a report on Tuesday. Royal Bank Of Canada lowered their price target on shares of Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday. Lake Street Capital set a $150.00 price target on shares of Inspire Medical Systems and gave the stock a “buy” rating in a report on Tuesday, August 5th. Finally, Wells Fargo & Company raised shares of Inspire Medical Systems from an “equal weight” rating to an “overweight” rating and lowered their price target for the stock from $101.00 to $90.00 in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $133.88.

Inspire Medical Systems Stock Down 2.6%

NYSE:INSP opened at $82.78 on Thursday. Inspire Medical Systems has a 52 week low of $70.77 and a 52 week high of $216.01. The firm has a 50 day moving average of $80.04 and a 200 day moving average of $112.23. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 56.31, a PEG ratio of 3.00 and a beta of 1.14.

Inspire Medical Systems announced that its board has initiated a stock buyback program on Monday, August 11th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to purchase up to 8.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Inspire Medical Systems

In other news, CFO Richard Buchholz sold 11,000 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $93.39, for a total value of $1,027,290.00. Following the transaction, the chief financial officer directly owned 44,867 shares of the company’s stock, valued at approximately $4,190,129.13. This trade represents a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of the business. Tempus Wealth Planning LLC lifted its stake in shares of Inspire Medical Systems by 36.8% in the third quarter. Tempus Wealth Planning LLC now owns 3,562 shares of the company’s stock worth $264,000 after buying an additional 959 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of Inspire Medical Systems by 18.6% in the third quarter. AlphaQuest LLC now owns 3,394 shares of the company’s stock worth $252,000 after buying an additional 533 shares in the last quarter. Truist Financial Corp increased its position in Inspire Medical Systems by 91.5% during the third quarter. Truist Financial Corp now owns 5,299 shares of the company’s stock worth $393,000 after purchasing an additional 2,532 shares during the last quarter. EFG Asset Management North America Corp. increased its position in Inspire Medical Systems by 157.1% during the third quarter. EFG Asset Management North America Corp. now owns 27,634 shares of the company’s stock worth $2,049,000 after purchasing an additional 16,887 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Inspire Medical Systems during the third quarter worth about $49,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.